5-MeO-MPT

  1. Home
  2. Wiki

5-MeO-MPT
Clinical data
Other names5-Methoxy-N-methyl-N-propyltryptamine
ATC code
  • None
Identifiers
  • N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-1-amine
PubChem CID
Chemical and physical data
FormulaC15H22N2O
Molar mass246.354 g·mol−1
3D model (JSmol)
  • CCCN(C)CCC1=CNC2=C1C=C(C=C2)OC
  • InChI=1S/C15H22N2O/c1-4-8-17(2)9-7-12-11-16-15-6-5-13(18-3)10-14(12)15/h5-6,10-11,16H,4,7-9H2,1-3H3
  • Key:YQHARYRPMKOJND-UHFFFAOYSA-N

5-MeO-MPT, also known as 5-methoxy-N-methyl-N-propyltryptamine, is a chemical compound of the tryptamine and 5-methoxytryptamine families.[1][2][3][4][5][6] It is closely related to the known psychedelic tryptamine and designer drug 4-HO-MPT as well as to methylpropyltryptamine (MPT).[7][8][9]

See also

[edit]

References

[edit]
  1. ^ Brandt SD, Freeman S, Fleet IA, Alder JF (September 2005). "Analytical chemistry of synthetic routes to psychoactive tryptamines. Part III. Characterisation of the Speeter and Anthony route to N,N-dialkylated tryptamines using CI-IT-MS-MS". The Analyst. 130 (9): 1258–1262. Bibcode:2005Ana...130.1258B. doi:10.1039/b504001a. PMID 16096671.
  2. ^ Brandt SD, Freeman S, Fleet IA, McGagh P, Alder JF (March 2005). "Analytical chemistry of synthetic routes to psychoactive tryptamines. Part II. Characterisation of the Speeter and Anthony synthetic route to N,N-dialkylated tryptamines using GC-EI-ITMS, ESI-TQ-MS-MS and NMR". The Analyst. 130 (3): 330–344. Bibcode:2005Ana...130..330B. doi:10.1039/b413014f. PMID 15724162.
  3. ^ Brandt SD, Tirunarayanapuram SS, Freeman S, Dempster N, Barker SA, Daley PF, et al. (2008). "Microwave-accelerated synthesis of psychoactive deuterated N,N-dialkylated-[α,α,β,β-d4]-tryptamines". Journal of Labelled Compounds and Radiopharmaceuticals. 51 (14): 423–429. doi:10.1002/jlcr.1557. ISSN 0362-4803. Retrieved 10 October 2025.
  4. ^ Brandt SD, Martins CP (2010). "Analytical methods for psychoactive N,N-dialkylated tryptamines". TrAC Trends in Analytical Chemistry. 29 (8): 858–869. doi:10.1016/j.trac.2010.04.008. Retrieved 10 October 2025.
  5. ^ Martins CP, Freeman S, Alder JF, Passie T, Brandt SD (2010). "Profiling psychoactive tryptamine-drug synthesis by focusing on detection using mass spectrometry". TrAC Trends in Analytical Chemistry. 29 (4): 285–296. doi:10.1016/j.trac.2010.01.009. Retrieved 10 October 2025.
  6. ^ Warren, A. (2024). Structural Evaluation of Mechanisms Underlying Serotonin Receptor Function (Doctoral dissertation, Icahn School of Medicine at Mount Sinai). https://www.proquest.com/openview/327b474bc8be3e1cabcd28a34c3b4f38/
  7. ^ Shulgin A, Shulgin A (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252. https://www.erowid.org/library/books_online/tihkal/tihkal23.shtml
  8. ^ Halberstadt AL, Chatha M, Klein AK, Wallach J, Brandt SD (May 2020). "Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species". Neuropharmacology. 167 107933. doi:10.1016/j.neuropharm.2019.107933. PMC 9191653. PMID 31917152. Table 4 Human potency data for selected hallucinogens. [...]
  9. ^ Tanaka R, Kawamura M, Hakamatsuka T, Kikura-Hanajiri R (2021). "Identification of six tryptamine derivatives as designer drugs in illegal products". Forensic Toxicology. 39 (1): 248–258. doi:10.1007/s11419-020-00556-5. ISSN 1860-8965. Retrieved 9 October 2025.
[edit]
Stub icon

This hallucinogen-related article is a stub. You can help Wikipedia by expanding it.